tiprankstipranks
Advertisement
Advertisement
Intellia Shareholders Back Board, Executive Pay and Auditor
PremiumCompany AnnouncementsIntellia Shareholders Back Board, Executive Pay and Auditor
2M ago
Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained
Premium
Ratings
Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained
2M ago
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
Premium
The Fly
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
3M ago
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
PremiumThe FlyIntellia Therapeutics reports Q1 EPS (81c), consensus (90c)
3M ago
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
Premium
Ratings
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
3M ago
Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100